Filing Flows › Sintx Technologies (SINT) › Guidance & outlook
Sintx Technologies (SINT) guidance and outlook
Sintx Technologies (SINT) reaffirmed its guidance on Oct 1, 2026: Revenue (segment) +380% for Q3 2026. Sintx Technologies' 10-Q filed Nov 5, 2026 makes 11 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | Q3 2026 | +380% | new |
From the earnings release filed Oct 1, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Nov 5, 2026
- We believe our product revenue will increase as we complete development and obtain regulatory clearance for our product candidates and secure opportunities to manufacture third party products with silicon nitride.
- We expect to incur additional research and development costs as we continue to develop new medical devices, related product candidates for antipathogenic applications, and other products which may increase our total research and development expenses.
- Management expects its OEM manufacturing operations and proprietary medical technology initiatives to remain complementary components of the Company's long-term growth strategy.
- While the Company expects its pricing initiatives and continued focus on higher-margin sales to support profitability, gross margins may fluctuate from period to period based on product mix, pricing, manufacturing efficiencies, customer demand, and the mix of product and grant and contract revenue.
- The condensed consolidated financial statements have been prepared assuming we will continue to operate as a going concern.
- We expect to continue incurring operating losses and using cash in operations as we advance our commercialization initiatives.
- We continue to evaluate opportunities to raise additional capital through equity and/or debt financing; however, there can be no assurance that additional funding will be available on acceptable terms, if at all.
- We continue to pursue initiatives intended to strengthen our financial position through increased commercial activity, improved operating efficiencies, and disciplined cost management.
- Management expects continued demand for our OEM products at levels above those experienced in prior periods, although quarterly sales volumes may fluctuate based on the timing and size of customer orders.
- Additionally, in October 2025, we entered into a sublease agreement for the SINTX Armor facility, which is expected to generate approximately $1.0 million in savings over the sublease term, as discussed in Note 12 to the condensed consolidated financial statements.
- We received approximately $1.5 million in cash and expect to receive approximately $0.2 million in deferred purchase price upon collection, subject to contractual adjustments.
Sintx Technologies' latest quarter
Sintx Technologies, Q3 2026: revenue $2.2M (+953% year over year), operating margin -74.7%, net loss $1.6M, operating cash flow −$1.4M. The chart follows the revenue to costs, profit and cash.
Questions
Did Sintx Technologies raise or lower its guidance?
Sintx Technologies (SINT) reaffirmed its guidance on Oct 1, 2026: Revenue (segment) +380% for Q3 2026.
What does Sintx Technologies expect?
We believe our product revenue will increase as we complete development and obtain regulatory clearance for our product candidates and secure opportunities to manufacture third party products with silicon nitride. We expect to incur additional research and development costs as we continue to develop new medical devices, related product candidates for antipathogenic applications, and other products which may increase our total research and development expenses. Management expects its OEM manufacturing operations and proprietary medical technology initiatives to remain complementary components o
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.